Glucose Transporter Type 1
"Glucose Transporter Type 1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A ubiquitously expressed glucose transporter that is important for constitutive, basal GLUCOSE transport. It is predominately expressed in ENDOTHELIAL CELLS and ERYTHROCYTES at the BLOOD-BRAIN BARRIER and is responsible for GLUCOSE entry into the BRAIN.
Descriptor ID |
D051272
|
MeSH Number(s) |
D12.776.157.530.500.500.500 D12.776.157.530.937.563.500 D12.776.543.585.500.500.500 D12.776.543.585.937.625.500
|
Concept/Terms |
Glucose Transporter Type 1- Glucose Transporter Type 1
- GLUT-1 Protein
- GLUT 1 Protein
- Solute Carrier Family 2, Facilitated Glucose Transporter, Member 1 Protein
- SLC2A1 Protein
- GLUT1 Protein
- Erythrocyte Glucose Transporter
- Glucose Transporter, Erythrocyte
|
Below are MeSH descriptors whose meaning is more general than "Glucose Transporter Type 1".
Below are MeSH descriptors whose meaning is more specific than "Glucose Transporter Type 1".
This graph shows the total number of publications written about "Glucose Transporter Type 1" by people in this website by year, and whether "Glucose Transporter Type 1" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1996 | 0 | 1 | 1 |
2002 | 0 | 2 | 2 |
2003 | 0 | 2 | 2 |
2006 | 1 | 1 | 2 |
2007 | 2 | 0 | 2 |
2008 | 0 | 3 | 3 |
2009 | 2 | 1 | 3 |
2010 | 1 | 0 | 1 |
2011 | 0 | 3 | 3 |
2012 | 0 | 1 | 1 |
2013 | 1 | 2 | 3 |
2014 | 1 | 1 | 2 |
2015 | 1 | 0 | 1 |
2016 | 2 | 0 | 2 |
2018 | 1 | 1 | 2 |
2019 | 2 | 1 | 3 |
2020 | 1 | 0 | 1 |
2021 | 2 | 0 | 2 |
2022 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Glucose Transporter Type 1" by people in Profiles.
-
GLUT1 Immunohistochemistry Is a Highly Sensitive and Relatively Specific Marker for Erythroid Lineage in Benign and Malignant Hematopoietic Tissues. Am J Clin Pathol. 2022 08 04; 158(2):228-234.
-
Targeting Glycolysis in Alloreactive T Cells to Prevent Acute Graft-Versus-Host Disease While Preserving Graft-Versus-Leukemia Effect. Front Immunol. 2022; 13:751296.
-
GLUT1 Expression in Tumor-Associated Neutrophils Promotes Lung Cancer Growth and Resistance to Radiotherapy. Cancer Res. 2021 05 01; 81(9):2345-2357.
-
Targeting In Vivo Metabolic Vulnerabilities of Th2 and Th17 Cells Reduces Airway Inflammation. J Immunol. 2021 03 15; 206(6):1127-1139.
-
Combined deletion of Glut1 and Glut3 impairs lung adenocarcinoma growth. Elife. 2020 06 23; 9.
-
p63 and SOX2 Dictate Glucose Reliance and Metabolic Vulnerabilities in Squamous Cell Carcinomas. Cell Rep. 2019 08 13; 28(7):1860-1878.e9.
-
Impaired enolase 1 glycolytic activity restrains effector functions of tumor-infiltrating CD8+ T cells. Sci Immunol. 2019 01 25; 4(31).
-
Myeloid Slc2a1-Deficient Murine Model Revealed Macrophage Activation and Metabolic Phenotype Are Fueled by GLUT1. J Immunol. 2019 02 15; 202(4):1265-1286.
-
Efferocytosis induces a novel SLC program to promote glucose uptake and lactate release. Nature. 2018 11; 563(7733):714-718.
-
Differential glucose requirement in skin homeostasis and injury identifies a therapeutic target for psoriasis. Nat Med. 2018 05; 24(5):617-627.